Evidence map›Paper›PMID 37225494›Full record

Observational studyInternal medicine (Tokyo, Japan)2023

A Comparison of Clinical Presentations in Coronavirus Disease 2019 Caused by Different Omicron Variants in Japan: A Retrospective Study.

Ryutaro Hirama, Kenichiro Takeda, Seiichiro Sakao, Hajime Kasai, Shizu Miyata, Kohei Shikano, Akira Naito, Mitsuhiro Abe, Takeshi Kawasaki, Ayako Shigeta and 3 more

Open access · diamondAbstract readObservational Study
In one paragraph

Observational study in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Repeated Syncope Following COVID-19 Infection.Internal medicine (Tokyo, Japan) · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ryutaro HiramaDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Kenichiro TakedaDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Seiichiro SakaoDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Hajime KasaiDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Shizu MiyataDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Kohei ShikanoDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Akira NaitoDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Mitsuhiro AbeDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Takeshi KawasakiDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Ayako ShigetaDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Taka-Aki NakadaDepartment of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Japan.
Hidetoshi IgariDepartment of Infectious Diseases, Chiba University Hospital, Japan.
Takuji SuzukiDepartment of Respirology, Graduate School of Medicine, Chiba University, Japan.
Chiba University · JPChiba University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective We evaluated the clinical differences in coronavirus disease 2019 (COVID-19) patients between the sixth wave with the Omicron BA.1/BA.2 dominant variant (from January to April 2022) and seventh wave with the Omicron BA.5 dominant variant (from July to August 2022). Methods This retrospective, single-center, observational study included COVID-19 patients admitted to our institution in the sixth wave (sixth-wave group) and the seventh wave (seventh-wave group). Inter-group comparisons of clinical presentations, the prognosis, and proportion of nosocomial infections were performed. Results A total of 190 patients were included (93 and 97 patients in the sixth- and seventh-wave groups, respectively). While there were no significant differences in severity, significantly more patients developed pneumonia caused by COVID-19 in the sixth-wave group than in the seventh-wave group. Although there was no marked difference in in-hospital deaths, more patients died from COVID-19 in the sixth-wave group than in the seventh-wave group. There were significantly more COVID-19 inpatients with nosocomial infections in the seventh-wave group than in the sixth-wave group. Pneumonia from COVID-19 was significantly more severe in the sixth-wave group than in the seventh-wave group. Conclusion COVID-19 patients in the seventh wave are at a lower risk of pneumonia than those in the sixth wave. However, even in the seventh wave, patients with underlying diseases have a risk of death because of the exacerbation of underlying diseases triggered by COVID-19.

Indexed as

COVID-19Cross InfectionHumansJapanRetrospective StudiesSARS-CoV-2coronavirus disease 2019nosocomial infectionomicron variantpneumonia

Identifiers

PMID37225494
PMCPMC10484773
OpenAlexW4377691746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.